LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media

March 13, 2024 updated by: Anabio R&D

Application of LiveSpo Navax® in the Treatment Support of Acute Rhinosinusitis and Acute Otitis Media

Acute respiratory tract infections (ARTIs), such as acute rhinosinusitis (ARS) and acute otitis media (AOM), are common worldwide and caused by viruses or bacteria entering the body through the mouth and nose. AOM frequently occurs in young children and is caused by bacterial reflux into the middle ear. ARS is a relatively common ARTIs and can occur at many ages. To accurately diagnose disease, careful clinical examination and accurate clinical judgment are required, as making a reasonable treatment regimen with the decision to use antibiotics. Probiotics have long been known to have beneficial effects on the digestive system. Not only limited to the gastrointestinal tract but probiotics are also known for their role in reducing infections in the respiratory system. Recently, the investigators have successfully conducted a clinical trial of nasal-spray Bacillus spore probiotics in children infected with respiratory syncytial virus (RSV), and the data show that the probiotics can rapidly and effectively relieve symptoms of RSV-induced ARTIs while exhibiting strong impacts in reducing viral load and inflammation. Here, the investigators conducted a study that directly spraying probiotics into the nose can effectively support to treatment of both ARS and AOM.

The aim of the study about to evaluate the safety and effectiveness of nasal-spraying probiotics containing spores of Bacillus subtilis and Bacillus clausii in the supportive treatment of patients with ARS and AOM.

Study Population: sample size is 120. Description of Sites: the study is carried out at Thai Binh Medical University Hospital and Thai Binh Children's Hospital.

Description of Study Intervention: 120 eligible patients are divided into 2 groups (n=60/group) including the ARS group and the ARS accompanied by the AOM (ARS & AOM) group. 60 patients in each of the above groups were randomly assigned to two subgroups (n=30/subgroup): Patients in the Control-ARS and Control-ARS & AOM subgroups received the routine treatment and three times per day nasal-spraying 0.9% NaCl physiological saline. In contrast, the patients in the Navax-ARS and Navax-ARS & AOM subgroups received three times per day nasal-spraying LiveSpo Navax® in addition to the same standard of care treatment. The standard treatment regimen is 3-7 days, depending on the severity of the disease when the patient arrives for the exam and the progression of the disease during the treatment period.

Study duration: 18 months

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Acute rhinosinusitis (ARS) is an inflammation of the nasal passages and the lining of the sinuses due to an infection. Clinical symptoms and signs of ARS include nasal blockage/obstruction/congestion or runny nose, sneezing, headache, sinus pain (facial pain), and loss of smell. According to statistics in the US, there are about 18-22 million ARS visits to the doctor each year that estimated cost of treatment of up to 11 billion dollars. Up to 28.9 million adults were diagnosed with rhinosinusitis, accounting for 11.6% of the population. In a 5-year statistics at the National Otorhinolaryngology Hospital of Vietnam, rhinosinusitis patients in the working age group from 16 to 50 years old account for 87%. Acute otitis media (AOM) is inflammation of the middle ear mucosa accompanied by effusion into the middle ear due to infection, which may be associated with the presence or absence of perforation of the tympanic membrane. Symptoms of AOM include fever, purulent discharge from the ear canal (ear discharge or otorrhea), earache (rubbing or pulling on the earlobe, tossing or turning, difficulty sleeping or crying), headache, and hearing loss temporary (poor response to sound), vomiting or diarrhea. AOM is children's most common ear disease and a common cause of hearing loss. About 90% of children under two years of age have had at least one episode, and about 80% of preschool children have otitis media. The prevalence is now about 20% at 2 years and 8% at the age of 8 years. Bacteria that cause acute rhinosinusitis and acute otitis media include S. pneumoniae, H. influenzae, M. catarrhalis, and S. aureus... Rhinosinusitis and bacterial otitis media usually require antibiotic treatment; however, inappropriate antibiotic therapy will increase drug resistance and side effects, thereby increasing medical costs. In recent years, the role of probiotics in respiratory diseases has also been mentioned in convincing studies. However, these probiotic products are mainly used orally, with very few products being prepared as nasal spray suspensions. Here, the investigators conducted a study that the direct spray of probiotics into the nose effectively supports treating acute rhinosinusitis and acute otitis media.

The objective was to investigate the symptomatic support treatment effects of the probiotic product LiveSpo Navax® as a liquid-suspension form containing Bacillus spores of safe B. subtilis ANA4 and B. clausii ANA39 strains in children and adults having ARS and children having ARS accompanied by AOM caused by bacteria, investigators evaluation of improved symptom efficacy of LiveSpo Navax® in patients; and measurement of changes in bacterial concentrations, and major cytokine indicators in the nasopharyngeal and ear samples before and after 3 days or 7 days using LiveSpo Navax®.

Methods: A randomized, blind, controlled clinical trial is conducted. The patients or parents of patients must provide the following information: full name, sex, age, address…After informed consent,120 eligible patients are divided into 2 groups (n = 60/group each) including the ARS group and the ARS accompanied by the AOM (ARS & AOM) group. 60 patients with ARS will be randomized into two subgroups (n = 30/subgroup): the control - acute rhinosinusitis subgroup (named Control - ARS subgroup) uses 0.9% NaCl physiological saline and an experimental - acute rhinosinusitis subgroup (called the Navax - ARS subgroup) use the probiotics LiveSpo Navax®. And similarly, 60 children with ARS accompanied by AOM will be randomized into two subgroups (n = 30/subgroup): the control - acute rhinosinusitis accompanied by acute otitis media group (named Control - ARS & AOM group) uses 0.9% NaCl physiological saline and an experimental - acute rhinosinusitis accompanied by acute otitis media group (called the Navax - ARS & AOM group) use the probiotics LiveSpo Navax®. The patient is given a coded spray in the form of a blind sample to ensure the study's objectivity. After the follow-up patient time, nasopharyngeal samples on both ARS and ARS accompanied by AOM groups and ear samples on the ARS accompanied by AOM group will be collected at day 0 and day 3 or/and 7 to evaluate potential reductions in bacteria load and modulation of cytokine, IgA, and the presence of probiotic spores in the patient's the nasopharyngeal and ear samples.

Real-time polymerase chain reaction (Real-time PCR) for detection of microorganisms in nasopharyngeal and ear samples: semi-quantitative assays for measuring changes in bacterial concentrations are conducted by the real-time PCR routine protocol, which has been standardized under International Organization for Standardization 5189:2012 (ISO 15189:2012) criteria and used in Vietnam National Children's Hospital. Detection of B. subtilis ANA4 and B. clausii ANA39 are also conducted by real-time PCR SYBR® Green (SYBR® Green is a dsDNA-binding dye), standardized routinely in Spobiotic Research Center, ANABIO R&D Ltd.

ELISA assays for cytokine levels: pro-inflammatory cytokines levels (pg/mL), including interleukin (IL-6, IL-8) and TNF-alpha, and immunoglobin A (ng/mL) are quantified using an enzyme-linked immunosorbent assay kit (ELISA) according to the manufacturer's instructions. The patients are monitored for symptoms of ARS and AOM at days 0, 3, or/and 7, depending on the degree of compliance with the follow-up re-examination of the outpatients. Doctors observe the patient's health conditions, and their patients of information are filled into medical records. During this study, patients are asked to abstain from the consumption of other probiotics, either via nasal spray or oral administration.

Data collection and statistical analysis: individual medical records are collected, and the patient's information is gathered and systematized. The efficacy of LiveSpo Navax® is evaluated and compared to 0.9% Sodium Chloride (NaCl) physiological saline based on the following clinical and sub-clinical criteria obtained in Navax and Control groups: (i) effective the symptomatic-relieving; (ii) the reduction levels (2^△Ct) of bacteria concentrations.△Ct for target genes is calculated as Ct (threshold cycle of real-time PCR assay) at day 3 or/and 7 - Ct at day 0 while Ct of internal control is adjusted to be equal among all samples; (iii) the reduction levels of IL-6, IL-8, and TNF-alpha cytokines and IgA. The tabular analysis is performed on dichotomous variables using the χ2 test or Fisher's exact test when the expected value of any cell is below five. Continuous variables are compared using the Wilcoxon test, t-test, or the Mann-Whitney test when data are not normally distributed. The correlations among the variables are assessed by Spearman's correlation analysis. Statistical and graphical analyses are performed on GraphPad Prism v8.4.3 software (GraphPad Software, CA, USA). The significance level of all analyses is set at p < 0.05. P-values.

Study Type

Interventional

Enrollment (Estimated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Vietnam
      • Thai Binh, Vietnam
        • Recruiting
        • Thai Binh University of Medicine and Pharmacy, Thai Binh Medical University Hospital and Thai Binh Children's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 months to 75 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients diagnosed with acute rhinosinusitis: sudden onset of two or more symptoms, one of which should be either nasal blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip); and/or facial pain/pressure; and/or reduction or loss of smell for <12 weeks. In children: sudden onset of two or more of the symptoms: nasal blockage/obstruction/congestion or discolored nasal discharge, or cough (daytime and night-time) for < 12 weeks
  • Patients diagnosed with acute rhinosinusitis accompanied by acute otitis media: patients from 6 months to 7 years old, suffer from onset ear discharge not caused by otitis external, the tympanic membrane was ruptured with purulent.
  • Patients are hospitalized or treated as outpatients but need periodic re-examination
  • Have a complete medical record or medical examination book
  • For patients under 18 years old, the patient's parents agreed to participate in the study that was explained and signed the study consent form.
  • Patients >18 years old: patients agreed to participate in the study, explained, and signed the study consent form.

Exclusion Criteria:

  • The patient did not agree to participate in the study.
  • There are not enough medical records or medical examination books.
  • The patient moves out of the treatment unit (not for professional reasons).
  • The outpatients but no periodic re-examination.
  • Patients with congenital deafness, or deafness due to neurological causes: meningitis, obstetric complications, ear poisoning...
  • Patients with congenital disease-causing disorders of maxillofacial development and mental and physical retardation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Control - Acute rhinosinusitis (ARS) subgroup

The Control - ARS subgroup receives the routine treatment and uses 0.9% NaCl physiological saline:

Routine treatment (at the Thai Binh Medical University Hospital) is as follows:

  • Oral-administrative antibiotics: Augmentin (Amoxicillin and Acid Clavulanic).
  • Oral-administrative expectorant: Acetylcysteine
  • Nasal- spraying decongestant: Xylometazoline (Otrivin®)
Drug: 0.9% NaCl physiological saline Nasal-spraying
0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
Other Names:
  • Registration number: VD-32723-19
Drug: Augmentin 500Mg Tablet
Augmentin (GlaxoSmithKline Pte, product declaration No. VN-20169-16) is an oral antibiotic available in the form of 625 mg tablets, which are prescribed as routine treatment for children and adults, respectively.
Other Names:
  • Registration number: VN-20169-16
Drug: Acetylcysteine
Acetylcysteine 200 mg (STADA Vietnam, product declaration No. VD-22667-15) is an oral expectorant, which is prescribed as routine treatment for children and adults, respectively.
Other Names:
  • Registration number: VD-22667-15
Drug: Xylometazoline Nasal
Otrivin (Xylometazoline 0.05%) (Novartis VietNam, product declaration No. VN-15558-12) is a nasal-spraying decongestant, which is prescribed as routine treatment for children and adults, respectively.
Other Names:
  • Otrivin® 0.05 % with Registration number: VN-15558-12
Experimental: Navax - Acute rhinosinusitis (ARS) subgroup

Navax - ARS subgroup receives the routine treatment and uses NaCl 0.9% plus B. subtilis and B. clausii at 5 billion Colony Forming Units (CFU)/5 mL (LiveSpo® Navax):

Routine treatment (at the Thai Binh Medical University Hospital) is as follows:

  • Oral-administrative antibiotics: Augmentin (Amoxicillin and Acid Clavulanic).
  • Oral-administrative expectorant: Acetylcysteine
  • Nasal- spraying decongestant: Xylometazoline (Otrivin®)
Drug: Augmentin 500Mg Tablet
Augmentin (GlaxoSmithKline Pte, product declaration No. VN-20169-16) is an oral antibiotic available in the form of 625 mg tablets, which are prescribed as routine treatment for children and adults, respectively.
Other Names:
  • Registration number: VN-20169-16
Drug: Acetylcysteine
Acetylcysteine 200 mg (STADA Vietnam, product declaration No. VD-22667-15) is an oral expectorant, which is prescribed as routine treatment for children and adults, respectively.
Other Names:
  • Registration number: VD-22667-15
Drug: Xylometazoline Nasal
Otrivin (Xylometazoline 0.05%) (Novartis VietNam, product declaration No. VN-15558-12) is a nasal-spraying decongestant, which is prescribed as routine treatment for children and adults, respectively.
Other Names:
  • Otrivin® 0.05 % with Registration number: VN-15558-12
Combination product: LiveSpo Navax®
In Vietnam, LiveSpo Navax® is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016
Other Names:
  • Registration number: No.210001337/PCBA-HN
Placebo Comparator: Control - ARS accompanied by the AOM (ARS & AOM) subgroup

The Control - ARS & AOM subgroup receives the routine treatment and uses 0.9% NaCl physiological saline:

Routine treatment (at the Thai Binh Children's Hospital) is as follows:

  • Oral-administrative antibiotics: Augmentin (Amoxicillin and Acid Clavulanic). Or injection or infusion-administrative antibiotics such as Imetoxim (Cefotaxime).
  • Antibiotic ear drops: Ciprofloxacin
  • Nasal- spraying decongestant: Xylometazoline (Otrivin®)
Drug: 0.9% NaCl physiological saline Nasal-spraying
0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
Other Names:
  • Registration number: VD-32723-19
Drug: Augmentin 500Mg Tablet
Augmentin (GlaxoSmithKline Pte, product declaration No. VN-20169-16) is an oral antibiotic available in the form of 625 mg tablets, which are prescribed as routine treatment for children and adults, respectively.
Other Names:
  • Registration number: VN-20169-16
Drug: Xylometazoline Nasal
Otrivin (Xylometazoline 0.05%) (Novartis VietNam, product declaration No. VN-15558-12) is a nasal-spraying decongestant, which is prescribed as routine treatment for children and adults, respectively.
Other Names:
  • Otrivin® 0.05 % with Registration number: VN-15558-12
Drug: Cefotaxime
Imetoxim 1g (Cefotaxime 1g) (Imexpharm Pharmaceutical, product declaration No. VD-26846-17) is an injection or infusion-administrative antibiotic, which is prescribed as routine treatment for children.
Other Names:
  • Imetoxim 1g with Registration number: VD-26846-17
Drug: Ciprofloxacin
Ciprofloxacin 0.3% (Vidipha Central Pharmaceutical, product declaration No. VD-15205-11) is an antibiotic ear drop, which is prescribed as routine treatment for children.
Other Names:
  • Registration number: VD-15205-11
Experimental: Navax - ARS accompanied by the AOM (ARS & AOM) subgroup

Navax - ARS & AOM subgroup receives the routine treatment and uses NaCl 0.9% plus B. subtilis and B. clausii at 5 billion CFU/5 mL (LiveSpo® Navax):

Routine treatment (at the Thai Binh Children's Hospital) is as follows:

  • Oral-administrative antibiotics: Augmentin (Amoxicillin and Acid Clavulanic). Or injection or infusion-administrative antibiotics such as Imetoxim (Cefotaxime).
  • Antibiotic ear drops: Ciprofloxacin
  • Nasal- spraying decongestant: Xylometazoline (Otrivin®)
Drug: Augmentin 500Mg Tablet
Augmentin (GlaxoSmithKline Pte, product declaration No. VN-20169-16) is an oral antibiotic available in the form of 625 mg tablets, which are prescribed as routine treatment for children and adults, respectively.
Other Names:
  • Registration number: VN-20169-16
Drug: Xylometazoline Nasal
Otrivin (Xylometazoline 0.05%) (Novartis VietNam, product declaration No. VN-15558-12) is a nasal-spraying decongestant, which is prescribed as routine treatment for children and adults, respectively.
Other Names:
  • Otrivin® 0.05 % with Registration number: VN-15558-12
Combination product: LiveSpo Navax®
In Vietnam, LiveSpo Navax® is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016
Other Names:
  • Registration number: No.210001337/PCBA-HN
Drug: Cefotaxime
Imetoxim 1g (Cefotaxime 1g) (Imexpharm Pharmaceutical, product declaration No. VD-26846-17) is an injection or infusion-administrative antibiotic, which is prescribed as routine treatment for children.
Other Names:
  • Imetoxim 1g with Registration number: VD-26846-17
Drug: Ciprofloxacin
Ciprofloxacin 0.3% (Vidipha Central Pharmaceutical, product declaration No. VD-15205-11) is an antibiotic ear drop, which is prescribed as routine treatment for children.
Other Names:
  • Registration number: VD-15205-11

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in percentages of patients with free acute rhinosinusitis symptoms
Time Frame: Day 3 compared to Day 0; Day 7 compared to Day 0
Changes in percentage (%) of acute rhinosinusitis patients with free acute rhinosinusitis symptoms include nasal blockage/obstruction/congestion or runny nose, sneezing, headache, sinus pain (facial pain), loss of smell
Day 3 compared to Day 0; Day 7 compared to Day 0
Changes in percentages of patients with free acute otitis media symptoms
Time Frame: Day 3 compared to Day 0
Changes in percentages (%) of acute otitis media patients with free acute otitis media symptoms include fever, purulent discharge from the ear canal (ear discharge or otorrhea), earache (rubbing or pulling on the earlobe, tossing or turning, difficulty sleeping or crying), headache, and hearing loss temporary (poor response to sound), vomiting or diarrhea.
Day 3 compared to Day 0

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in infection bacterial concentrations can cause acute rhinosinusitis (ARS) and acute otitis media (AOM)
Time Frame: Day 3 compared to Day 0 and/or Day 7 compared to Day 0
Changes in infection bacterial (S. pneumoniae, H. influenzae, M. catarrhalis) concentrations in nasopharyngeal samples on both ARS and ARS accompanied by AOM groups and ear samples in the ARS accompanied by AOM group, as indicated by real-time PCR threshold cycle (Ct) values
Day 3 compared to Day 0 and/or Day 7 compared to Day 0
Changes in cytokines level
Time Frame: Day 3 compared to Day 0 and/or Day 7 compared to Day 0
Changes in levels of tumor necrosis factor-α (TNF-α) (pg/mL), interleukin-6 (IL-6) (pg/mL), and interleukin-8 (IL-8) (pg/mL)... in nasopharyngeal samples on both ARS and ARS accompanied by AOM groups and ear samples in the ARS accompanied by AOM group
Day 3 compared to Day 0 and/or Day 7 compared to Day 0
Changes in immunoglobulin A level
Time Frame: Day 3 compared to Day 0 and/or Day 7 compared to Day 0
Changes in level of immunoglobulin A (IgA) (ng/mL) in nasopharyngeal samples on both ARS and ARS accompanied by AOM groups and ear samples in the ARS accompanied by AOM group
Day 3 compared to Day 0 and/or Day 7 compared to Day 0

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Anabio R&D

Collaborators

Thai Binh University of Medicine and Pharmacy

Investigators

  • Principal Investigator: Thanh Khieu Huu, MD.,PhD, Thai Binh University of Medicine and Pharmacy
  • Principal Investigator: Binh Nguyen Thanh, Assoc. Prof., Thai Binh University of Medicine and Pharmacy
  • Principal Investigator: Anh Nguyen Thị Vân, Assoc. Prof., Anabio R&D Ltd

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 28, 2021

Primary Completion (Estimated)

June 1, 2024

Study Completion (Estimated)

June 1, 2024

Study Registration Dates

First Submitted

March 7, 2023

First Submitted That Met QC Criteria

April 5, 2023

First Posted (Actual)

April 7, 2023

Study Record Updates

Last Update Posted (Actual)

March 15, 2024

Last Update Submitted That Met QC Criteria

March 13, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TNLS.2021.03
  • 872/HĐĐĐ (Other Identifier: Thai Binh University of Medicine and Pharmacy)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data or samples share that will be coded, with no PHI include. Approval of the request and execution of all applicable agreements (i.e. a material transfer agreement) are prerequisites to the sharing of data with the requesting party.

IPD Sharing Time Frame

Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.

IPD Sharing Access Criteria

Access to trial IPD can be requested by qualified researchers engaging in independent scientific research and will be provided following review and approval of a study protocol, informed consent form (ICF), and clinical study report (CSR). For more information or to submit a request, please contact clinicaltrial.probiotics@gmail.com

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Upper Respiratory Tract Infections

Clinical Trials on 0.9% NaCl physiological saline Nasal-spraying

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe